A Pilot Study of Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
- Participants will receive Darbepoetin alfa through an injection under the skin, about
28-35 days after their allogeneic stem cell transplant. They will continue to receive
the study drug once every three weeks for a maximum of four doses.
- Blood tests will be performed at weeks 3, 6, 9 and 12. The blood tests done at week
three will check to make sure the participant has enough iron in their system. If not,
they will need to take an iron supplement. Participants will also take a folate
supplement to help cell growth and reproduction.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate the percentage of patients achieving a target hemoglobin of 11 g/dL or greater by day 100 following allogeneic stem cell transplantation.
Eric Jacobsen, MD
Dana-Farber Cancer Institute
United States: Institutional Review Board
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|